Anaphylaxis, Asthma, Chronic Idiopathic Urticaria, Eczema, Food Allergy, Mast Cell Activation Syndrome, Mastocytosis
Conditions
Keywords
mast cell, allergy, genomic, biomarkers
Brief summary
Activation of mast cells in the immune system is known to cause allergic reactions sometimes with severe systemic symptoms. The investigators have recently developed a blood-based mast cell activation diagnostic test in which levels of functional activation in-vitro in primary cultured mast cells generated from the peripheral blood of single individuals can be assessed. It is the hypothesis that the test can be used to predict the potential state of in-vivo mast cell activation in any individual based on the functional activation profiles exhibited by their cultured mast cells. The investigators now wish to translate their in-vitro findings in a pilot study to disease groups where mast cell activation is expected to be high. These include highly allergic individuals; those with chronic idiopathic urticaria; those with mastocytosis; and those with the mast cell activation syndrome. Furthermore, they will use the functional genomics approach to identify gene expression biomarkers that are correlated with such diseases. The results will be compared with data that have been collected from a cohort of healthy control blood donors.
Detailed description
The objective of this study is to assess whether patients with severe allergic diseases exhibit high levels of mast cell activation as determined by the mast cell activation diagnostic test the investigators have developed. They anticipate that patients with history of severe allergic reactions will show up as high responders in the blood-based mast cell activation diagnostic test. Moreover, using microarray analysis as the approach for gene expression studies, they anticipate further that genomics biomarkers that are correlated with the high functional activation of the in-vitro mast cells derived from these patients can be readily identified. About 100 ml of peripheral venous blood from individual patients will be drawn into heparinized syringes and collected in a blood-collecting bag/tube containing silica. The bag/tube will be promptly processed for the generation of primary human mast cell cultures using the protocol that has previously been developed \[Inflammation Research 66: 25 (2017). After culturing for 9 weeks, the resulting human mast cells will be analyzed for both their functional activity in terms of histamine release in response to the activation of high-affinity Immunoglobulin E (IgE) receptors in these cells and their gene expression profiles using microarray analysis. The in-vitro functional and genomics data will be correlated with specific diagnoses and measurements of blood prostaglandin D2 (PGD2), PGD2 metabolites, tryptase and histamine levels in blood. For mediator assays, plasma from each subject will be collected after the cluster of differentiation 34 positive (CD34+) isolation step and the samples will be aliquoted and frozen at -80 degrees centigrade for subsequent analysis.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
Any patients with the above diagnoses -
Exclusion criteria
Children \< 18 years old; those who are unwilling or unable to donate blood; pregnant mothers. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mast Cell Activation Test Results for Validation Group | Mast cells studied after 9 weeks in culture | Mast Cell Activation Test results of high/low level of house dust mite sensitivity by using normal donor cultured mast cells for validation. |
| Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation | Mast cells studied after 9 weeks in culture | Patient's serum was incubated with mast cells derived from normal donors for detection of mast cell activation as evidenced by histamine release. |
| Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity | Mast cells studied after 9 weeks in culture | percentage of total histamine release by normal average responder mast cells that had been activated with patient's serum |
| Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE | Mast cells studied after 9 weeks in culture | percentage of total histamine release by patient's mast cells that had been activated with anti-IgE |
| Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen | Mast cells studied after 9 weeks in culture | Percentage of total histamine release when patient's mast cells were activated with patient's own serum and Der p2. Each patient's results are reported individually. |
| Cell Yield Per 100ml Blood | Mast cells studied after 9 weeks in culture | Cell yield of patient's mast cell culture after 9 weeks in culture as an index of cell growth and differentiation. |
Countries
Hong Kong
Participant flow
Recruitment details
19 patients were recruited in the study. 12 were used for validation. 7 were used for patient-specific testing. Therefore, there were 1 validation group and 7 individuals' result.
Participants by arm
| Arm | Count |
|---|---|
| Validation Group Mast cell activation test employing normal donor cultured mast cells and allergic patient serum samples | 12 |
| SH#1 Male patient, Total IgE: 28918KU/L; Der p2IgE: 64.4KU/L; clinical diagnosis: Eczema | 1 |
| SH#2 Male patient, Total IgE: 22311KU/L; Der p2IgE: 91.24KU/L; clinical diagnosis: Eczema | 1 |
| SH#3 Female patient, Total IgE: 5333KU/L; Der p2IgE: \>100KU/L; clinical diagnosis: Eczema | 1 |
| SH#4 Male patient, Total IgE: 4070KU/L; Der p2IgE: \>100KU/L; clinical diagnosis: Eczema, Urticaria | 1 |
| SH#5 Male patient, Total IgE: 379KU/L; Der p2IgE: 0.15KU/L; clinical diagnosis: Exercise-induced anaphylaxis | 1 |
| SH#6 Female patient, Total IgE: 13KU/L; Der p2IgE: \<0.1KU/L; clinical diagnosis: Mast cell activation syndrome | 1 |
| SH#7 Male patient, Total IgE: 67KU/L; Der p2IgE: None KU/L; clinical diagnosis: Urticaria | 1 |
| Total | 19 |
Baseline characteristics
| Characteristic | SH#7 | Total | SH#1 | SH#2 | SH#3 | SH#4 | SH#5 | SH#6 | Validation Group |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants | 19 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 12 Participants |
| Clinical diagnosis Eczema | 0 Participants | 7 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 4 Participants |
| Clinical diagnosis Eczema and Urticaria | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Clinical diagnosis Exercise-induced anaphylaxis | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Clinical diagnosis Mast cell activation syndrome | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Clinical diagnosis Rhinitis | 0 Participants | 5 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 5 Participants |
| Clinical diagnosis Urticaria | 1 Participants | 4 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 18 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 12 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Region of Enrollment Hong Kong | 1 participants | 7 participants | 1 participants | 1 participants | 1 participants | 1 participants | 1 participants | 1 participants | 12 participants |
| Sex: Female, Male Female | 0 Participants | 11 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 9 Participants |
| Sex: Female, Male Male | 1 Participants | 8 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 12 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 |
| other Total, other adverse events | 0 / 12 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 |
| serious Total, serious adverse events | 0 / 12 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 |
Outcome results
Cell Yield Per 100ml Blood
Cell yield of patient's mast cell culture after 9 weeks in culture as an index of cell growth and differentiation.
Time frame: Mast cells studied after 9 weeks in culture
Population: Mast cells derived from 7 allergic patients were analysed and reported individually. Patients in the validation group were not measured for this outcome and their samples were only used to validate the assay.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Validation Group | Cell Yield Per 100ml Blood | 14045000 Cell yield per 100ml blood |
| SH#1 | Cell Yield Per 100ml Blood | 2895522 Cell yield per 100ml blood |
| SH#2 | Cell Yield Per 100ml Blood | 115294 Cell yield per 100ml blood |
| SH#3 | Cell Yield Per 100ml Blood | 625263 Cell yield per 100ml blood |
| SH#4 | Cell Yield Per 100ml Blood | 4867778 Cell yield per 100ml blood |
| SH#5 | Cell Yield Per 100ml Blood | 352000 Cell yield per 100ml blood |
| SH#6 | Cell Yield Per 100ml Blood | 1400000 Cell yield per 100ml blood |
Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation
Patient's serum was incubated with mast cells derived from normal donors for detection of mast cell activation as evidenced by histamine release.
Time frame: Mast cells studied after 9 weeks in culture
Population: Serum samples were obtained from 19 patients in total, of whom 12 were in the validation group. The other 7 patients were studied more extensively in the trial and their data is reported individually in this section and thereafter.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Validation Group | Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation | 0 Participants |
| SH#1 | Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation | 1 Participants |
| SH#2 | Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation | 0 Participants |
| SH#3 | Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation | 0 Participants |
| SH#4 | Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation | 0 Participants |
| SH#5 | Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation | 0 Participants |
| SH#6 | Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation | 0 Participants |
| SH#7 | Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation | 0 Participants |
Mast Cell Activation Test Results for Validation Group
Mast Cell Activation Test results of high/low level of house dust mite sensitivity by using normal donor cultured mast cells for validation.
Time frame: Mast cells studied after 9 weeks in culture
Population: Mast cells were cultured from blood of normal donors to validate the (Mast Cell Activation) MAT assay. The serum samples were obtained from allergic patients with sensitivities to Der p2 and used for passive sensitization of normal donor mast cells followed by their activation by Der p2 allergen. Data were collected only from the validation group.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Validation Group | Mast Cell Activation Test Results for Validation Group | High level of house dust mite sensitivity | MAT positive | 6 Participants |
| Validation Group | Mast Cell Activation Test Results for Validation Group | High level of house dust mite sensitivity | MAT negative | 2 Participants |
| Validation Group | Mast Cell Activation Test Results for Validation Group | Low level of house dust mite sensitivity | MAT positive | 0 Participants |
| Validation Group | Mast Cell Activation Test Results for Validation Group | Low level of house dust mite sensitivity | MAT negative | 4 Participants |
Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity
percentage of total histamine release by normal average responder mast cells that had been activated with patient's serum
Time frame: Mast cells studied after 9 weeks in culture
Population: Mast cells derived from the validation group is reported as a group (mean +/-SD). The other 7 allergic patients were analysed and reported individually as explained earlier.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Validation Group | Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity | 2.15 percentage of histamine released | Standard Deviation 0.71 |
| SH#1 | Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity | 32.1 percentage of histamine released | — |
| SH#2 | Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity | 3.3 percentage of histamine released | — |
| SH#3 | Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity | 2.8 percentage of histamine released | — |
| SH#4 | Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity | 3.4 percentage of histamine released | — |
| SH#5 | Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity | 5.1 percentage of histamine released | — |
| SH#6 | Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity | 3.2 percentage of histamine released | — |
| SH#7 | Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity | 3.8 percentage of histamine released | — |
Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE
percentage of total histamine release by patient's mast cells that had been activated with anti-IgE
Time frame: Mast cells studied after 9 weeks in culture
Population: Mast cells derived from 7 allergic patients were analysed and reported individually. Patients in the validation group were not measured for this outcome and their samples were only used to validate the assay.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Validation Group | Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE | 11.5 percentage of histamine release |
| SH#1 | Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE | 38.3 percentage of histamine release |
| SH#2 | Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE | 69.6 percentage of histamine release |
| SH#3 | Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE | 47.9 percentage of histamine release |
| SH#4 | Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE | 36.3 percentage of histamine release |
| SH#5 | Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE | 45.5 percentage of histamine release |
| SH#6 | Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE | 41.6 percentage of histamine release |
Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen
Percentage of total histamine release when patient's mast cells were activated with patient's own serum and Der p2. Each patient's results are reported individually.
Time frame: Mast cells studied after 9 weeks in culture
Population: Mast cells derived from 7 allergic patients were analysed and reported individually. Patients in the validation group were not measured for this outcome and their samples were only used to validate the assay.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Validation Group | Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen | 24.5 percentage of histamine release |
| SH#1 | Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen | 54.7 percentage of histamine release |
| SH#2 | Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen | 79 percentage of histamine release |
| SH#3 | Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen | 8.4 percentage of histamine release |
| SH#4 | Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen | 0.2 percentage of histamine release |
| SH#5 | Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen | 0.2 percentage of histamine release |
| SH#6 | Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen | 0 percentage of histamine release |